Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target
Updated: Nov 5, 2022
Milestone payment to Dragonfly is triggered by dosing of first patient in Phase 1 clinical trial
Dragonfly Therapeutics, Inc. ("Dragonfly"), today announced that the first patient has been dosed in a clinical trial being conducted by Merck, known as MSD outside the United States and Canada, to evaluate a solid tumor targeting TriNKET developed by Dragonfly. Dragonfly will receive an undisclosed milestone payment triggered by this event.
"Across both our 1.0 and 2.0 collaborations, Merck has been an extraordinary partner in oncology, immune disorders and other fields," said Bill Haney, co-founder and CEO of Dragonfly Therapeutics. "We are delighted that the first immunotherapy candidate from our initial collaboration has advanced into the clinic, and equally enthusiastic by the progress we are making together on bringing Dragonfly's TriNKET technology to targets that address other indications."
The companies' collaboration, initially focused on a number of solid tumor targets, began in October 2018. The collaboration was subsequently expanded in 2020 with a multi-target agreement to develop and commercialize additional natural killer ("NK") cell engager immunotherapies in oncology, infectious disease and immune disorders. Merck licensed this first TriNKET immunotherapy candidate from Dragonfly in November 2020.
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel bispecific antibody technology to harness the body's innate immune system to bring breakthrough treatments to patients. Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platform that are progressing toward the clinic, as well as productive collaborations with Merck, Abbvie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc./ https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne E. Deconinck | anne@dragonflytx.com



While preparing notes on social security programmes for a competitive examination, I wanted to include schemes that focus on workers with limited access to formal benefits. PM Shram Yogi Mandan Yojana UPSC is a useful search topic for understanding the scheme from an examination perspective. Its objectives, target beneficiaries, pension arrangement, and implementation details are important areas to study. Organising these points under clear headings can make revision easier and help connect the scheme with broader social welfare topics.
I tried a few prompt seen ideas recently, and some of the results turned out better than I expected. It’s fun to experiment with different styles.
I like modern hindu baby names that have a traditional meaning but still sound fresh. It’s a nice way to balance culture and personal preference.
MapQuest directions can help volunteers reach a community garden, find the check-in table, and plan their drive for an annual planting day in a new neighborhood before the morning session.
Career preparation is a valuable benefit of structured security education. Online training can introduce professional expectations, workplace communication, incident documentation, and basic operational procedures. Learners may use this knowledge to understand job descriptions and identify skills they need to develop further. Employment requirements vary, so completing a course alone does not guarantee a position. Researching local opportunities, preparing an accurate résumé, and securityguardschool checking licensing rules can help prospective candidates make informed decisions about entering the security industry.